The expression of angiogenic growth factors, their corresponding receptors and functional responsiveness to inhibition of VEGFR/PDGFR signalling provides strong evidence that leiomyosarcoma patients with VEGFR- and/or PDGFR-positive tumor samples might benefit from anti-angiogenic treatment by inhibition of both autocrine stimulation of tumor cell growth and paracrine stimulation of angiogenesis. This evidence concerns the gene PDGFRB and neoplasm.